Known as Aviator.

Abbott releases details on stage 3 hepatitis C registrational program Abbott today released details on its phase 3 hepatitis C registrational program following promising outcomes from its phase 2b clinical trial, known as Aviator, presented at the Annual Meeting of the American Association for the analysis of Liver Disease in Boston. Yet another stage 3 trial shall study triple-DAAs, with ribavirin, in sufferers with cirrhosis for 12 or 24 weeks. An interview with Dr Chhatwal The phase 3 plan, which is open up for enrollment currently, will include more than 2,000 individuals with HCV genotype 1, with trial sites in 29 countries.Related StoriesStudy evaluates performance of antiretroviral treatment in HIV-infected childrenNew computer model predicts levels of HIV treatment engagementPitt Public Health launches study to promote health among ageing gay and bisexual guys with HIV’Latest breakthroughs, including excellent results from the CAPRISA 004 microbicide trial, possess reenergized prevention study, and around the world, thousands of research participants and hundreds of experts and trial site personnel will work together find brand-new HIV prevention options.